Winners from the latest round of Inflation Reduction Act (IRA) price negotiations

td { padding: 10px; }

The latest round of IRA price negotiations has revealed which pharma manufacturers were able to best defend their pricing despite having no walk-away power and limited leverage. By comparing predicted ceiling prices with the final negotiated outcomes, clear patterns begin to emerge. Our experts’ analysis highlights which companies came closest to the best-case scenario and what these early signals may mean for future CMS negotiations.

The negotiation between pharmaceutical manufacturers and the Centers for Medicare & Medicaid Services (CMS) as part of the Inflation Reduction Act (IRA) is different from typical negotiations. In most negotiations, both sides have something to gain from a successful outcome of the process and both sides typically have the power to walk away from the negotiating table if they are unable to come to a mutual agreement. Unfortunately for manufacturers, there is nothing to gain from IRA negotiations as…